Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Judge 

Pfizer Inc. diskutieren

Pfizer Inc.

WKN: 852009 / Symbol: PFE / Name: Pfizer / Aktie / Pharmazeutika / Large Cap /

23,87 €
1,29 %

Einschätzung Buy
Rendite (%) -22,53 %
Kursziel 71,41
Veränderung
Endet am 02.10.24

Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $75.00 price target on the stock.
Ratings data for PFE provided by MarketBeat

Einschätzung Buy
Rendite (%) -19,00 %
Kursziel 36,98
Veränderung
Endet am 16.10.24

Pfizer Inc. (NYSE: PFE) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $39.00 price target on the stock, up previously from $38.00.
Ratings data for PFE provided by MarketBeat

Einschätzung Buy
Rendite (%) -21,05 %
Kursziel 31,25
Veränderung
Endet am 16.10.24

Pfizer Inc. (NYSE: PFE) had its price target lowered by analysts at BMO Capital Markets from $44.00 to $33.00. They now have an "outperform" rating on the stock.
Ratings data for PFE provided by MarketBeat

Einschätzung Buy
Rendite (%) -19,65 %
Kursziel 39,74
Veränderung
Endet am 17.10.24

Pfizer Inc. (NYSE: PFE) had its price target lowered by analysts at Truist Financial Co. from $62.00 to $42.00. They now have a "buy" rating on the stock.
Ratings data for PFE provided by MarketBeat

Einschätzung Buy
Rendite (%) -11,88 %
Kursziel 68,49
Veränderung
Endet am 20.11.24

Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $75.00 price target on the stock.
Ratings data for PFE provided by MarketBeat

Einschätzung Buy
Rendite (%) -11,88 %
Kursziel 38,83
Veränderung
Endet am 04.12.24

Pfizer Inc. (NYSE: PFE) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $42.00 price target on the stock.
Ratings data for PFE provided by MarketBeat

Einschätzung Buy
Rendite (%) 1,27 %
Kursziel 32,76
Veränderung
Endet am 14.12.24

Pfizer Inc. (NYSE: PFE) had its price target lowered by analysts at Truist Financial Co. from $42.00 to $36.00. They now have a "buy" rating on the stock.
Ratings data for PFE provided by MarketBeat

Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for PFE provided by MarketBeat

Einschätzung Buy
Rendite (%) -10,40 %
Kursziel 41,10
Veränderung
Endet am 09.01.25

Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PFE provided by MarketBeat

Einschätzung Buy
Rendite (%) -6,08 %
Kursziel 41,47
Veränderung
Endet am 31.01.25

Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PFE provided by MarketBeat

Einschätzung Buy
Rendite (%) -7,18 %
Kursziel 33,22
Veränderung
Endet am 23.02.25

Pfizer Inc. (NYSE: PFE) is now covered by analysts at Guggenheim. They set a "buy" rating and a $36.00 price target on the stock.
Ratings data for PFE provided by MarketBeat

Einschätzung Buy
Rendite (%) -3,40 %
Kursziel 41,51
Veränderung
Endet am 01.03.25

Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PFE provided by MarketBeat

Einschätzung Buy
Rendite (%) -8,28 %
Kursziel 41,73
Veränderung
Endet am 01.04.25

Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PFE provided by MarketBeat

Einschätzung Buy
Rendite (%) -3,03 %
Kursziel 42,30
Veränderung
Endet am 15.04.25

Pfizer Inc. (NYSE: PFE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $45.00 price target on the stock.
Ratings data for PFE provided by MarketBeat